Transgene SA (OTCMKTS:TRGNF – Get Free Report) was the recipient of a large increase in short interest in May. As of May 15th, there was short interest totaling 1,095 shares, an increase of ∞ from the April 30th total of 0 shares. Based on an average trading volume of 0 shares, the short-interest ratio is currently ∞ days.
Transgene Stock Performance
OTCMKTS TRGNF remained flat at $0.85 during trading hours on Monday. The company’s fifty day moving average price is $0.93 and its 200 day moving average price is $0.95. Transgene has a 12-month low of $0.85 and a 12-month high of $1.08.
About Transgene
Transgene is a clinical-stage biotechnology company headquartered in Strasbourg, France, dedicated to designing and developing targeted immunotherapies for cancer and infectious diseases. Founded in 1979, the company combines expertise in virology, gene engineering and immunology to create viral-based vectors that deliver therapeutic genes or antigens directly into patient tissues. In the United States, Transgene’s American Depositary Receipts trade under the symbol TRGNF.
The company’s proprietary platforms include an oncolytic vaccine technology that harnesses genetically modified viruses to selectively infect and destroy tumor cells while stimulating systemic anti-tumor immunity.
Featured Articles
- Five stocks we like better than Transgene
- Why These Three Big Buybacks Are Sending Very Different Signals to Investors
- Drone Stocks Soar As Pentagon Considers Funding, Including a Trump-Linked Name
- Braze Blazes Ahead on Q1 2027 Earnings Beat, Raised Guidance
- Are the 3 Newest Members of the $1 Trillion Market Cap Club the Latest Sign of an AI Bubble?
Receive News & Ratings for Transgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transgene and related companies with MarketBeat.com's FREE daily email newsletter.
